What semaglutide is. And where it comes from
Semaglutide is a synthetic 30-amino-acid peptide. An analogue of human GLP-1 (glucagon-like peptide-1), an incretin hormone the gut releases in response to food. Native GLP-1 has a half-life of about two minutes because it is rapidly cleaved by the enzyme DPP-4. Semaglutide was engineered to resist that cleavage.
Two specific modifications extend its half-life: a fatty-acyl side chain that binds serum albumin, and a substitution at position 8 that blocks DPP-4. The result is a half-life of roughly one week, enabling once-weekly subcutaneous dosing in Ozempic and Wegovy.
Semaglutide activates the same receptor pathway that endogenous GLP-1 does, the key difference is that it does so for approximately a week rather than for two minutes.
Mechanism, in plain English
GLP-1 receptors are widely distributed, on pancreatic beta cells, on neurons in the hindbrain and hypothalamus, on gut enteroendocrine cells, and on vascular endothelium. Semaglutide activates the same receptor pathway that endogenous GLP-1 does, with three clinically relevant downstream effects:
- Glucose-dependent insulin secretion. Beta cells release more insulin when blood glucose is high; the effect tapers as glucose normalizes, which is part of why semaglutide has a low intrinsic hypoglycemia risk as monotherapy.
- Glucagon suppression. Glucagon output from alpha cells is suppressed, reducing hepatic glucose output.
- Satiety signaling. Central pathways involved in appetite and reward respond to GLP-1 receptor activation, producing reduced food intake.
Want all 24 weight loss and metabolism compounds in one place?
The Peptexa Weight Loss and Metabolism guide covers every compound in this category, mechanism, evidence level, and FDA status for each.
What the trial evidence shows
The evidence base is broad and reproducible across independent groups. Two trials most cited:
STEP 1. NEJM 2021, Wilding et al.: 1,961 adults with obesity randomized to semaglutide 2.4 mg or placebo alongside lifestyle intervention. Mean weight change at 68 weeks: -14.9% semaglutide vs -2.4% placebo.
SELECT. NEJM 2023, Lincoff et al.: 17,604 adults with established cardiovascular disease. Semaglutide reduced the composite primary outcome (cardiovascular death, non-fatal MI, non-fatal stroke) by 20% over a mean 39.8 months (HR 0.80, 95% CI 0.72-0.90).
The SELECT trial established that semaglutide reduces cardiovascular events in people with obesity and established CVD, independent of its weight-loss effect.
FDA status (this month)
Semaglutide is FDA-approved under three brand names: Ozempic (subcutaneous injection, type 2 diabetes, 2017), Rybelsus (oral tablet, type 2 diabetes, 2019, the first oral GLP-1 receptor agonist), and Wegovy (subcutaneous injection, chronic weight management, 2021; cardiovascular risk-reduction indication expanded 2024 on the basis of SELECT).
Semaglutide is NOT approved via compounding pharmacy under ordinary circumstances. The FDA has taken enforcement action against compounded semaglutide. Last reviewed 2026-08-09.
Common synonyms researchers use
Semaglutide · NN9535 · NNC0113-0217 (early Novo Nordisk designations) · GLP-1 RA (class label) · Ozempic, Wegovy, Rybelsus (brand references).
Safety & adverse-event landscape
Most common adverse effects in published trials are gastrointestinal: nausea, vomiting, diarrhea, constipation, dose-related and tend to attenuate with continued exposure. The product label carries warnings regarding thyroid C-cell tumors (boxed warning based on rodent carcinogenicity data), pancreatitis, gallbladder disease, and hypoglycemia risk when co-administered with insulin secretagogues. Always consult a qualified healthcare provider before any health decision involving semaglutide.
Frequently asked questions
Want this in your inbox weekly?
Get the Peptexa Top-5 free, five compounds, mechanism-led. One email a week. No spam.
The full Weight Loss & Metabolism reference
24 compounds. Mechanism, evidence level, and FDA status for every one. Free PDF, no email required.
Get the Weight Loss & Metabolism Guide →